San Diego, CA, United States of America

Mary Matyskiela

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Mary Matyskiela: Innovator in Cereblon Research

Introduction

Mary Matyskiela is a prominent inventor based in San Diego, CA. She has made significant contributions to the field of biochemistry, particularly in the study of cereblon and its implications in therapeutic development. With a total of 3 patents, her work is paving the way for new treatments in various diseases.

Latest Patents

Mary's latest patents include innovative methods for measuring small molecule affinity to cereblon. One of her notable inventions describes a complex that comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, along with a Cy5-conjugated small molecule. This invention is crucial for identifying therapeutic compounds. Another significant patent focuses on methods for screening cereblon modifying compounds. This method involves obtaining a sample, determining protein levels, and selecting compounds that do not induce degradation of SALL, which is vital for treating diseases or disorders.

Career Highlights

Mary Matyskiela is currently associated with Celgene Corporation, where she continues to advance her research in cereblon. Her work has garnered attention in the scientific community, contributing to the understanding of protein interactions and their therapeutic potential.

Collaborations

Mary has collaborated with notable colleagues such as Philip Chamberlain and Godrej Khambatta, enhancing the scope and impact of her research.

Conclusion

Mary Matyskiela's innovative work in cereblon research exemplifies her dedication to advancing medical science. Her patents reflect her commitment to developing effective therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…